Mellozzan[® ](melatonin) have gained marketing approval in Germany and Austria

As the first countries outside of Scandinavia, EQL's key product Mellozzan^® has now gained marketing approval by the Health Authorities in Germany and Austria, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH & Co. KG. Launch of Mellozzan in Germany and Austria are planned for 2024, subject to reimbursement approvals and manufacturing capabilities. In addition to Germany and Austria the licensee also has ongoing work for registrations and subsequent launches in the UK, Finland and Switzerland. Earlier this year Medice launched Mellozzan in Denmark and Norway.

In addition to the countries covered by Medice, other partners for Mellozzan^® are in various stages of registration in France, Italy, Spain, the Netherlands, Turkey and Kazakhstan. Furthermore, EQL has entered into a global license agreement covering 89 countries with Adalvo for Mellozzan^®.
 

About Mellozzan^®

Mellozzan^® contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan^® is also indicated for the short-term treatment of jet lag in adults.
 

About EQL

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 28 niche generics (i.e., generics with limited competition apart from the original drug) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2024 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.

About Medice

Medice Arzneimittel Pütter GmbH & Co. KG, founded in 1949 and headquartered in Iserlohn (Germany), is a fully integrated pharmaceutical company with own GxP capabilities in development, manufacturing and pan-European and international distribution of pharmaceuticals and medical devices. It is the core of “Medice – The Health Family” aiming to improve patient management by offering high quality innovative drugs, non-pharmacological interventions and value adding services. For more information, please visit www.medice.com.

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 25 niche generics (i.e., generics with limited competition apart from the original drug) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2023 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.